Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Amo Pharma Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, showing that each pending matter is being handled by a different specialist. This distribution ensures that the company's current applications are being reviewed independently across different technical groups at the USPTO, which may lead to varying prosecution timelines and outcomes for each filing.
CORNET, JEAN P is the busiest examiner with 1 pending office action. Since there are 2 distinct examiners for the 2 total pending office actions, the workload is evenly distributed across the portfolio. No single examiner or art unit holds a majority of the company's pending cases, which provides a level of diversification in the prosecution process for these matters. This structure allows the company to test different claim strategies across 2 distinct art units simultaneously, reducing the impact of any single examiner's interpretation.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| SCHMITT, MICHAEL J | 1 | 56.8% | +20.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18108320 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | SCHMITT, MICHAEL J | 73d overdue |
| 18134955 | METHODS OF TREATING PHELAN MCDERMID SYNDROME USING FARNESYL DIBENZODIAZEPINONES | CORNET, JEAN P | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18134955 | METHODS OF TREATING PHELAN MCDERMID SYNDROME USING FARNESYL DIBENZODIAZEPINONES | CORNET, JEAN P | 1628 | §103 | Final Rejection | 49d overdue | Pending | Apr 14, 2023 |
| 18108320 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | SCHMITT, MICHAEL J | 1629 | §102 | Final Rejection | 73d overdue | Pending | Feb 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial